Mizuho Maintains Outperform on Haemonetics, Raises Price Target to $140

Benzinga Newsdesk www.benzinga.com Positive 90.7%

Neg 0% Neu 0% Pos 90.7%

Mizuho analyst Anthony Petrone maintains Haemonetics (NYSE:HAE) with a Outperform and raises the price target from $95 to $140.